Physician profile
Lauren L Sum
NPI 1972522399
$895.98
in general payments reported to CMS, 2019-2025
13 companies · $72.35 in 2025
The $72.35 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2021: $212 · 2022: $211 · 2023: $174 · 2025: $72.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $271.36 | 2022-2023 | Senza |
| Grt US Holding, INC. | $118.78 | 2021 | |
| Comsort, INC | $100.00 | 2019 | |
| Merck Sharp & Dohme LLC | $92.39 | 2019 | |
| Cardiovascular Systems INC. | $67.23 | 2021 | |
| Globus Medical, INC. | $66.93 | 2023-2025 | Senza, Mini Fragment System |
| Horizon Therapeutics Plc | $46.20 | 2019-2023 | Krystexxa |
| Stryker Corporation | $34.80 | 2019-2021 | |
| Amgen INC. | $28.45 | 2025 | Krystexxa |
| Paratek Pharmaceuticals, INC. | $20.12 | 2023 | Nuzyra |
| Abbott Laboratories | $19.58 | 2023 | Proclaim |
| Kowa Pharmaceuticals America, INC. | $15.73 | 2022 | |
| Bioventus LLC | $14.41 | 2023 | Durolane |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Sum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.